Pluristem Therapeutics EBITDA 2011-2026 | PSTI

Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.^[1]

EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.

EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.

However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.

Annual EBITDA Pluristem Therapeutics

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-21.9 M	-21.9 M	-26.9 M	-40.5 M	-49.3 M	-27.9 M	-33.6 M	-31.7 M	-25.8 M	-21.2 M	-23.2 M	-25.9 M	-21.2 M	-14.6 M	-10.8 M

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
-10.8 M	-49.3 M	-26.4 M

Quarterly EBITDA Pluristem Therapeutics

2025-Q4	2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-6.38 M	-6.22 M	-	-	-4.89 M	-5.13 M	-	-	-	-5.31 M	-	-	-6.68 M	-6.82 M	-13.4 M	-10.5 M	-10.8 M	-11.1 M	-21.6 M	-14.2 M	-13.1 M	-8.39 M	-12.4 M	-8.39 M	-6.37 M	-6.73 M	-5.52 M	-6.73 M	-8.33 M	-8.47 M	-	-9.05 M	-8.47 M	-6.92 M	-7.44 M	-6.92 M	-6.65 M	-6 M	-5.54 M	-6 M	-4.23 M	-5.03 M	-3.2 M	-5.03 M	-6.3 M	-5.12 M	-5.3 M	-5.12 M	-6.99 M	-4.4 M	-6.05 M	-4.4 M	-4.88 M	-4.06 M	-4.61 K	-4.06 M	-2.12 K	-4.24 M	-1.92 M	-4.24 M

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
-2.12 K	-21.6 M	-6.83 M

References

Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.

EBITDA of other stocks in the Biotechnology industry

Issuer	EBITDA	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	-508 M	-	2.43 %	$ 254 M	Germany
AgeX Therapeutics AGE	-23.9 M	-	-10.17 %	$ 12.2 K	USA
I-Mab IMAB	13.8 M	-	-	$ 866 M	China
Midatech Pharma plc MTP	-7 M	-	-18.52 %	$ 27.3 M	Britain
Alexion Pharmaceuticals, Inc. ALXN	3.11 B	-	-	$ 40.3 B	USA
Biophytis SA BPTS	-26.8 M	-	-13.47 %	$ 169 M	France
Genfit SA GNFT	31.8 M	-	2.54 %	$ 160 B	France
EyeGate Pharmaceuticals, Inc. EYEG	-8.18 M	-	-1.52 %	$ 24.7 M	USA
Athira Pharma ATHA	-101 M	-	-	$ 269 M	USA
BioNTech SE BNTX	15.3 B	-	-	$ 27.2 B	Germany
Институт стволовых клеток человека ISKJ	220 M	-	-	-	Russia
Checkmate Pharmaceuticals CMPI	-61.4 M	-	-	$ 231 M	USA
INmune Bio INMB	-47.3 M	$ 1.52	-1.3 %	$ 37.6 M	USA
Exelixis EXEL	901 M	$ 48.7	9.64 %	$ 13.2 B	USA
ACADIA Pharmaceuticals ACAD	232 M	$ 21.48	-3.89 %	$ 3.56 B	USA
Fortress Biotech FBIO	-69.8 M	-	-	$ 71.1 M	USA
Advaxis ADXS	-35.9 M	-	-9.65 %	$ 45.9 M	USA
Esperion Therapeutics ESPR	60.4 M	$ 3.15	1.19 %	$ 655 M	USA
Can-Fite BioPharma Ltd. CANF	-9.93 M	-	-	$ 5.51 M	Israel
Aeterna Zentaris AEZS	-8.67 M	-	5.93 %	$ 314 M	Canada
Aeglea BioTherapeutics AGLE	-242 M	-	-	$ 1.01 B	USA
CureVac N.V. CVAC	-412 M	-	-	$ 867 M	Germany
Applied Genetic Technologies Corporation AGTC	-16.2 M	-	-	$ 26.5 M	USA
AIkido Pharma AIKI	-55.6 M	-	1.93 %	$ 17.4 M	USA
Akero Therapeutics AKRO	-285 M	-	-	$ 3.67 B	USA
Aptose Biosciences APTO	22 K	-	-45.71 %	$ 1.2 M	Canada
Aptinyx APTX	-62.4 M	-	-39.0 %	$ 4.57 M	USA
Akouos AKUS	-84.3 M	-	0.23 %	$ 488 M	USA
Albireo Pharma ALBO	-123 M	-	-0.23 %	$ 916 M	USA
Allakos ALLK	-190 M	-	-	$ 28.6 M	USA
AlloVir ALVR	-46.1 M	-	4.14 %	$ 49.1 M	USA
Arcutis Biotherapeutics ARQT	-11.5 M	$ 24.17	3.2 %	$ 3.08 B	USA
Allena Pharmaceuticals ALNA	-47.3 M	-	3.16 %	$ 1.9 M	USA
Ampio Pharmaceuticals AMPE	122 K	-	-11.43 %	$ 502 K	USA
Applied Molecular Transport AMTI	-124 M	-	-	$ 10.1 M	USA
Alpine Immune Sciences ALPN	-57.6 M	-	-	$ 2.17 B	USA
Aileron Therapeutics ALRN	-50.6 M	-	10.36 %	$ 9.8 M	USA
Applied Therapeutics APLT	-64.5 M	-	-	$ 8.42 M	USA
Aravive ARAV	-70 M	-	-13.39 %	$ 1.45 M	USA
Aridis Pharmaceuticals ARDS	-29.5 M	-	17.91 %	$ 11.1 M	USA
CRISPR Therapeutics AG CRSP	-645 M	$ 55.08	5.15 %	$ 4.95 B	Schweiz
Avenue Therapeutics ATXI	-3.08 M	-	-52.27 %	$ 4.45 M	USA
Autolus Therapeutics plc AUTL	-262 M	$ 1.7	3.66 %	$ 452 M	Britain
AVROBIO AVRO	10.8 M	-	1083.1 %	$ 745 M	USA
Ayala Pharmaceuticals AYLA	-37.3 M	-	-	$ 7.46 M	Israel
Завод ДИОД DIOD	85.9 M	-	-	-	Russia
Фармсинтез LIFE	-22.6 M	-	-	-	Russia
AstraZeneca PLC AZN	1.06 B	-	-	$ 96.9 B	Britain
Galapagos NV GLPG	-166 M	$ 28.81	1.48 %	$ 2.69 B	Belgium
Genmab A/S GMAB	6.57 B	$ 27.89	1.34 %	$ 17.2 B	Danmark